Liquid Biopsy: From Research Tool to Regulated Clinical Diagnostic — What the Transition Requires

The Liquid Biopsy Transition Moment

Liquid biopsy — the analysis of circulating tumor DNA, circulating tumor cells, and other tumor-derived biomarkers in blood and other body fluids — has been in clinical research use for over a decade. The transition from research tool to regulated clinical diagnostic, which has been in progress for the past five years, is now reaching a critical phase: the evidence base for clinical utility is maturing, the regulatory pathways are more clearly defined, and the reimbursement frameworks are beginning to catch up with the clinical evidence.

The organizations and development programs that will define the clinical liquid biopsy market are the ones that navigate the transition from research tool to regulated diagnostic most effectively — building the analytical validation, clinical validation, and regulatory evidence packages that transform research-grade assays into clinically actionable, reimbursed diagnostic tests.

The Analytical Validation Challenge

Liquid biopsy assays face analytical validation challenges that are specific to the low-allele-frequency detection problem that defines ctDNA analysis. Circulating tumor DNA constitutes a small and variable fraction of the total circulating cell-free DNA in a patient’s blood — as low as 0.01% or less in early-stage disease. Detecting tumor-derived variants at these allele frequencies requires analytical sensitivity and specificity that exceed the requirements of conventional tumor tissue NGS assays.

Four analytical validation requirements that are specific to liquid biopsy:

Limit of detection characterization: the LOD for ctDNA variant detection must be characterized across the full range of allele frequencies expected in the intended clinical use population, not just at the variant allele frequencies that are technically detectable in laboratory conditions. Clinical samples with low tumor fraction will have ctDNA allele frequencies that approach the assay’s LOD, and the analytical validation must characterize performance at these clinically relevant allele frequencies.

Pre-analytical variation management: ctDNA is highly susceptible to pre-analytical variation. The time between blood draw and plasma separation, the collection tube type, the storage conditions, and the plasma isolation method all affect ctDNA yield and integrity in ways that can produce false negative results if not controlled. Clinical utility validation must include pre-analytical specifications that are achievable in real-world clinical practice, not only in controlled research settings.

Clonal hematopoiesis disambiguation: circulating cell-free DNA contains variants derived from clonal hematopoiesis — age-related somatic mutations in hematopoietic stem cells that are not tumor-derived. Distinguishing clonal hematopoiesis variants from ctDNA variants requires paired white blood cell sequencing or computational methods that identify CH-characteristic variant patterns. The regulatory evidence package for a liquid biopsy assay must address CH disambiguation explicitly.

Tumor heterogeneity and spatial sampling: ctDNA represents a sampling of shed DNA from tumor cells across all tumor sites in the body — potentially including sites not identifiable by conventional imaging. This spatial sampling characteristic is one of liquid biopsy’s theoretical advantages over tissue biopsy but also creates interpretive complexity: variants detected in ctDNA that are absent from the tissue biopsy may reflect subclonal heterogeneity that is present in metastatic sites not sampled by the tissue biopsy, not errors in either assay.

The Clinical Validation Evidence Requirements

The FDA’s approach to clinical validation for liquid biopsy assays reflects the regulatory framework for companion diagnostics when the assay is used for therapy selection, and the framework for screening and monitoring tests when the assay is used for cancer detection or treatment response assessment.

For therapy selection applications: liquid biopsy assays used to identify patients eligible for targeted therapy — EGFR mutation detection in NSCLC for EGFR inhibitor eligibility, for example — require clinical performance data demonstrating concordance with tissue biopsy results as the reference standard, and in some cases clinical outcome data demonstrating that therapy selection based on liquid biopsy results produces clinical benefit comparable to tissue-biopsy-guided selection.

The concordance evidence requirement is more complex than it appears. Discordance between liquid biopsy and tissue biopsy results can reflect assay error in either direction, tumor heterogeneity, or temporal differences between sample collection time points. The clinical validation framework must address the clinical interpretation of discordant results and the recommended clinical action when liquid biopsy and tissue biopsy results conflict.

For treatment monitoring applications: liquid biopsy assays used to monitor ctDNA dynamics as a marker of treatment response and minimal residual disease are being validated in clinical studies across multiple tumor types. The regulatory evidence requirements for treatment monitoring assays depend on whether the assay result is used to make treatment decisions — in which case a companion diagnostic regulatory pathway may apply — or to provide prognostic information that informs clinical management without triggering specific treatment decisions.

The Multi-Cancer Early Detection Category

Multi-cancer early detection — liquid biopsy assays designed to detect cancer signals across multiple tumor types in asymptomatic individuals — represents the most commercially ambitious and regulatory complex liquid biopsy application category. Grail’s Galleri test is the most advanced commercial program in the category, with a growing body of clinical evidence and early NHS adoption in the UK.

The regulatory pathway for MCED tests in the US involves the FDA’s framework for screening tests, which requires clinical validity evidence — demonstration that the test detects cancer earlier than standard of care — and clinical utility evidence — demonstration that earlier detection leads to improved clinical outcomes. The clinical utility evidence requirement is the most demanding component: demonstrating that detecting cancer earlier with MCED leads to improved survival or other meaningful clinical outcomes requires large, long-term randomized or observational studies that are expensive to conduct and take years to complete.

The reimbursement pathway for MCED tests is even less defined than the regulatory pathway. CMS’s approach to coverage for novel screening tests requires evidence of net health benefit in the Medicare population, a standard that the current MCED evidence base does not yet fully satisfy for a positive national coverage determination.

The Strategic Implication for Liquid Biopsy Development Programs

Liquid biopsy is a genuinely transformative diagnostic modality that is transitioning from research tool to clinical standard of care in specific applications faster than the regulatory and reimbursement frameworks have anticipated. The development programs that will capture the commercial opportunity are the ones that invest in the analytical and clinical validation evidence required for regulatory authorization, engage the FDA and payers early in development to align on evidence requirements, and design validation studies that generate both regulatory approval evidence and payer coverage evidence simultaneously.

The liquid biopsy development programs that treat analytical validation, clinical validation, and reimbursement strategy as sequential activities — completing each before beginning the next — will arrive at the commercial market years after the programs that treat all three as parallel development tracks.

About the Author

Ashish Yadav is a Life Sciences AI, Regulatory Strategy, and Enterprise Technology executive with 20+ years across pharma, biotech, MedTech, diagnostics, and digital health. Founder of PrecisionPulse Consulting LLC and creator of the ARIA™ AI Governance Framework.

Connect on LinkedIn: linkedin.com/in/ashishyadav-executive